Molecular pathways: Emerging roles of mammalian Sirtuin SIRT7 in cancer

Clinical Cancer Research

Volumn 20, Issue 7, 2014, Pages 1741-1746

  Paredes, Silvana ^a,b   Villanova, Lidia ^a,b,c   Chua, Katrin F ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HISTONE H3; LYSINE; RIBOSOME RNA; SIRTUIN 7; CHROMATIN; HISTONE; SIRT7 PROTEIN, HUMAN; SIRTUIN;

AGING; ARTICLE; BIOGENESIS; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER THERAPY; CARCINOGENICITY; CATALYSIS; CELL TRANSFORMATION; CHROMATIN; DEACETYLATION; DISEASE COURSE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INACTIVATION; EPIGENETICS; GENE EXPRESSION REGULATION; HUMAN; IN VIVO STUDY; MALIGNANT TRANSFORMATION; METABOLISM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RIBOSOME; RNA SYNTHESIS; SIGNAL TRANSDUCTION; TUMOR GROWTH; ACETYLATION; CARCINOGENESIS; CELL PROLIFERATION; GENETICS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY;

ACETYLATION; CARCINOGENESIS; CELL PROLIFERATION; CHROMATIN; HISTONES; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; SIRTUINS;

EID: 84898716870     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1547     Document Type: Article

References (50)

1. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD- dependent histone deacetylase. Nature 2000;403:795-800. (Pubitemid 30111843)
2. Kaeberlein M, Andalis AA, Fink GR, Guarente L. High osmolarity extends life span in Saccharomyces cerevisiae by a mechanism related to calorie restriction. Mol Cell Biol 2002;22:8056-66 (Pubitemid 35217313)
3. Du J, Zhou Y, Su X, Yu JJ, Khan S, Jiang H, et al. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 2011;334:806-9.
4. Mao Z, Hine C, Tian X, Van Meter M, Au M, Vaidya A, et al. SIRT6 promotes DNA repair under stress by activating PARP1. Science 2011;332:1443-6.
5. Martinez-Redondo P, Vaquero A. The diversity of histone versus nonhistone sirtuin substrates. Genes Cancer 2013;4:148-63.
6. Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 2010;5:253-95.
7. Barber MF, Michishita-Kioi E, Xi Y, Tasselli L, Kioi M, Moqtaderi Z, et al. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature 2012;487:114-8.
8. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 2005;16:4623-35. (Pubitemid 41416446)
9. Hein N, Hannan KM, George AJ, Sanij E, Hannan RD. The nucleolus: an emerging target for cancer therapy. Trends Mol Med 2013;19:643-54.
10. Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 2008;40:897-903. (Pubitemid 351913645)
11. Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 2009;174:1619- 28.
12. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435:1262-6. (Pubitemid 40943093)
13. Manuyakorn A, Paulus R, Farrell J, Dawson NA, Tze S, Cheung-Lau G, et al. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J Clin Oncol 2010;28:1358-65.
14. Ferrari R, Pellegrini M, Horwitz GA, Xie W, Berk AJ, Kurdistani SK. Epigenetic reprogramming by adenovirus e1a. Science 2008;321:1086-8.
15. Horwitz GA, Zhang K, McBrian MA, Grunstein M, Kurdistani SK, Berk AJ. Adenovirus small e1a alters global patterns of histone modification. Science 2008;321:1084-5.
16. Makkonen H, Jaaskelainen T, Pitkanen-Arsiola T, Rytinki M, Waltering KK, Matto M, et al. Identification of ETS-like transcription factor 4 as a novel androgen receptor target in prostate cancer cells. Oncogene 2008;27:4865-76.
17. Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009;458:97-101.
18. Day BW, Stringer BW, Spanevello MD, Charmsaz S, Jamieson PR, Ensbey KS, et al. ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1. Neuro-oncology 2011;13:1202-12.
19. Kim JK, Noh JH, Jung KH, Eun JW, Bae HJ, Kim MG, et al. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology 2013;57:1055-67.
20. Shin J, He M, Liu Y, Paredes S, Villanova L, Brown K, et al. SIRT7 Represses Myc activity to suppress ER stress and prevent fatty liver disease. Cell Rep 2013;5:654-65.
21. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer 2010;10:254-66
22. Soucek L, Evan GI. The ups and downs of Myc biology. Curr Opin Genet Dev 2010;20:91-5.
23. Liu H, Radisky DC, Yang D, Xu R, Radisky ES, Bissell MJ, et al. MYC suppresses cancer metastasis by direct transcriptional silencing of alphav and beta3 integrin subunits. Nat Cell Biol 2012;14:567-74
24. Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, Gunawardane RN, et al. MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc Natl Acad Sci U S A 2010;107:3698-703.
25. Cappellen D, Schlange T, Bauer M, Maurer F, Hynes NE. Novel c-MYC target genes mediate differential effects on cell proliferation and migration. EMBO Rep 2007;8:70-6. (Pubitemid 46043803)
26. Hubbi ME, Hu H, Kshitiz, Gilkes DM, Semenza GL. Sirtuin-7 inhibits the activity of hypoxia-inducible factors. J Biol Chem 2013;288:20768-75.
27. Vakhrusheva O, Smolka C, Gajawada P, Kostin S, Boettger T, Kubin T, et al. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res 2008;102:703-10. (Pubitemid 351457857)
28. Drygin D, Rice WG, Grummt I. The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer. Annu Rev Pharmacol Toxicol 2010;50:131-56.
29. Ford E, Voit R, Liszt G, Magin C, Grummt I, Guarente L. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev 2006;20:1075-80.
30. Chen S, Seiler J, Santiago-Reichelt M, Felbel K, Grummt I, Voit R. Repression of RNA polymerase I upon stress is caused by inhibition of RNA-dependent deacetylation of PAF53 by SIRT7. Mol Cell 2013;52:303-13.
31. Tsai YC, Greco TM, Boonmee A, Miteva Y, Cristea IM. Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription. Mol Cell Proteomics 2012;11:60-76.
32. Tsai YC, Greco TM, Cristea IM. SIRT7 plays a role in ribosome biogenesis and protein synthesis. Mol Cell Proteomics 2014;13:73-83.
33. Kawai T, Fan J, Mazan-Mamczarz K, Gorospe M. Global mRNA stabilization preferentially linked to translational repression during the endoplasmic reticulum stress response. Mol Cell Biol 2004;24:6773-87. (Pubitemid 38944356)
34. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
35. Chi P, Allis CD, Wang GG. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 2010;10:457-69.
36. Ashraf N, Zino S, Macintyre A, Kingsmore D, Payne AP, George WD, et al. Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer 2006;95:1056-61. (Pubitemid 44606833)
37. Frye R. "SIRT8" expressed in thyroid cancer is actually SIRT7. Br J Cancer 2002;87:1479. (Pubitemid 36044326)
38. Mason DX, Keppler D, Zhang J, Jackson TJ, Seger YR, Matsui S, et al. Defined genetic events associated with the spontaneous in vitro transformation of EIA/Ras-expressing human IMR90 fibroblasts. Carcinogenesis 2006;27:350-9.
39. Papa FR. Endoplasmic reticulum stress, pancreatic beta-cell degeneration, and diabetes. Cold Spring Harb Perspect Med 2012;2:a007666.
40. Doyle KM, Kennedy D, Gorman AM, Gupta S, Healy SJ, Samali A. Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders. J Cell Mol Med 2011;15:2025-39.
41. Zhao K, Chai X, Clements A, Marmorstein R. Structure and autoregulation of the yeast Hst2 homolog of Sir2. Nat Struct Biol 2003;10:864-71. (Pubitemid 37187660)
42. Tennen RI, Berber E, Chua KF. Functional dissection of SIRT6: identification of domains that regulate histone deacetylase activity and chromatin localization. Mech Ageing Dev 2010;131:185-92.
43. Sinclair DA, Guarente L. Small-molecule allosteric activators of sirtuins. Annu Rev Pharmacol Toxicol 2014;54:363-80
44. Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 2013;339:1216-9.
45. Lakshminarasimhan M, Rauh D, Schutkowski M, Steegborn C. Sirt1 activation by resveratrol is substrate sequence-selective. Aging 2013;5:151-4.
46. Pan PW, Feldman JL, Devries MK, Dong A, Edwards AM, Denu JM. Structure and biochemical functions of SIRT6. J Biol Chem 2011;286:14575-87.
47. Feldman JL, Baeza J, Denu JM. Activation of the protein deacetylase SIRT6 by long-chain fatty acids and widespread deacylation by mammalian sirtuins. J Biol Chem 2013;288:31350-6.
48. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007;450:712-6. (Pubitemid 350207685)
49. Milne JC, Denu JM. The Sirtuin family: therapeutic targets to treat diseases of aging. Curr Opin Chem Biol 2008;12:11-7.
50. Cen Y. Sirtuins inhibitors: the approach to affinity and selectivity. Biochim Biophys Acta 2010;1804:1635-44.